Linked Life Data

2904394

Source:http://linkedlifedata.com/resource/pubmed/id/2904394

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
1989-1-26
pubmed:abstractText
Nine healthy volunteers were studied on the seventh day of dosing at 21:00 h with nizatidine 150 mg (N 150), nizatidine 300 mg (N 300), ranitidine 300 mg (R 300), or placebo, given in a predetermined random order. The double-blind 24 hour studies, using the Royal Free Hospital standard protocol, simultaneously measured intragastric acidity and plasma gastrin concentration. Compared with placebo, subjects responded to dosing with each H2-antagonist by a significant decrease of 24 hour intragastric acidity (N 150-45%; N 300-49% R 300-56%; p less than 0.01) and a significant rise of plasma gastrin concentration (N 150 + 20%; N 300 + 27%; R 300 + 58%; p less than 0.01). All three drug regimens caused similar significant decreases of nocturnal acidity (N 150-72%; N 300-79%; R 300-85%; p less than 0.01) and increases of nocturnal plasma gastrin concentration (N 150 + 41%; N300 + 52%; R 300 + 80%; p less than 0.01). Dosing with ranitidine 300 mg at 21:00 h also caused a simultaneous significant decrease of morning acidity (-32%; p less than 0.05) with a significant increase of plasma gastrin concentration (+36%; p less than 0.05), but the antisecretory effects of nizatidine 150 or 300 mg at 21:00 h were only observed during the night, with no effect during the morning. No drug regimen had any effect on acidity or plasma gastrin in the afternoon or early evening.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/2904394, http://linkedlifedata.com/resource/pubmed/commentcorrection/2904394-2578420, http://linkedlifedata.com/resource/pubmed/commentcorrection/2904394-2859413, http://linkedlifedata.com/resource/pubmed/commentcorrection/2904394-2879782, http://linkedlifedata.com/resource/pubmed/commentcorrection/2904394-2892251, http://linkedlifedata.com/resource/pubmed/commentcorrection/2904394-2892255, http://linkedlifedata.com/resource/pubmed/commentcorrection/2904394-2892261, http://linkedlifedata.com/resource/pubmed/commentcorrection/2904394-2979226, http://linkedlifedata.com/resource/pubmed/commentcorrection/2904394-3283919, http://linkedlifedata.com/resource/pubmed/commentcorrection/2904394-3510144, http://linkedlifedata.com/resource/pubmed/commentcorrection/2904394-3546004, http://linkedlifedata.com/resource/pubmed/commentcorrection/2904394-3715400, http://linkedlifedata.com/resource/pubmed/commentcorrection/2904394-3858976, http://linkedlifedata.com/resource/pubmed/commentcorrection/2904394-6434053
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0017-5749
pubmed:author
pubmed:issnType
Print
pubmed:volume
29
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1364-9
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
Twenty four hour intragastric acidity and plasma gastrin concentration in healthy volunteers taking nizatidine 150 mg, nizatidine 300 mg, ranitidine 300 mg, or placebo at 21:00 h.
pubmed:affiliation
Academic Department of Medicine, Royal Free Hospital School of Medicine, London.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial